<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884517</url>
  </required_header>
  <id_info>
    <org_study_id>BAT-8003-001-CR</org_study_id>
    <nct_id>NCT03884517</nct_id>
  </id_info>
  <brief_title>Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer</brief_title>
  <official_title>An Open, Escalating Phase I Clinical Trial of BAT8003 (for Injection) on the Safety, Tolerability and Pharmacokinetics for Patients With Advanced Epithelial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Thera Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Thera Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is divided into three periods. Dosing will be the first day of each cycle, 21 days
      per cycle. The first period is the day of first study drug delivery until the 21st day, that
      is, the first treatment cycle. The DLT observation, exploration of MTD, safety of single
      administration, tolerance and pharmacokinetics, immunity Original research will happen during
      this period. The second period is a 2-8 dosing cycle, with multiple doses of tolerance,
      pharmacokinetics, immunogenicity studies, and preliminary efficacy evaluations. After a 2-4
      cycle study, patients with good tolerance and no tumor progression will continue to the 5-8
      cycle dosing study. The third period is to expand the study. After exploring the MTD, the
      investigator and the sponsor can discuss to extend another 10-30 cases in a safe and
      effective dose group to further study the effectiveness and safety of BAT8003 and its
      pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose-limiting toxicity (DLT)</measure>
    <time_frame>3weeks</time_frame>
    <description>safety and tolerability endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD)</measure>
    <time_frame>3weeks</time_frame>
    <description>safety and tolerability endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve（AUC）</measure>
    <time_frame>no more than 24weeks</time_frame>
    <description>pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum drug concentration（Cmax)</measure>
    <time_frame>no more than 24weeks</time_frame>
    <description>pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life period（t1/2）</measure>
    <time_frame>no more than 24weeks</time_frame>
    <description>pharmacokinetic endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum drug time（Tmax）</measure>
    <time_frame>no more than 24weeks</time_frame>
    <description>pharmacokinetic endpoint</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Solid Cancer</condition>
  <arm_group>
    <arm_group_label>BAT8003 0.2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 0.5mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 1mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，1mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，2mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 4mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，4mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 6mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，6mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 8mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，8mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAT8003 10mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，10mg/kg，intravenous infusion, sample size 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplification group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAT8003</intervention_name>
    <description>Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result</description>
    <arm_group_label>Amplification group</arm_group_label>
    <arm_group_label>BAT8003 0.2mg/kg</arm_group_label>
    <arm_group_label>BAT8003 0.5mg/kg</arm_group_label>
    <arm_group_label>BAT8003 10mg/kg</arm_group_label>
    <arm_group_label>BAT8003 1mg/kg</arm_group_label>
    <arm_group_label>BAT8003 2mg/kg</arm_group_label>
    <arm_group_label>BAT8003 4mg/kg</arm_group_label>
    <arm_group_label>BAT8003 6mg/kg</arm_group_label>
    <arm_group_label>BAT8003 8mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient or his legal representative signs the informed consent form and fully
             understands the content, process of the study and possible adverse reactions of the
             study, and is willing to follow up and image evaluation according to the time
             specified in the protocol.

          2. Age 18-75 years old (including boundary value), gender is not limited;

          3. advanced epithelial cancer who are ineffective, unable to receive, or absent from
             standard treatment, histologically or cytologically confirmed;

          4. positive Trop2 expression;

          5. At least one measurable tumor lesions according to RECIST 1.1(Evaluation Standard for
             Solid Tumor Efficacy 1.1);

          6. The US Eastern Cooperative Oncology Group (ECOG) scores 0 to 1;

          7. Expected survival period ≥ 3 months;

          8. proper Laboratory test indicators:

          9. Echocardiographic examination of left ventricular ejection fraction (LVEF) ≥ 50%;

         10. The treatment for solid cancer has been completed for at least 3 weeks, and has
             basically recovered from the adverse reactions of previous treatment (≤1 grade
             according to CTCAE5.0（Common Terminology Criteria for Adverse Events 5.0） standard,
             except for hair loss);

        Exclusion Criteria:

          1. Have active hepatitis B (HBV) or hepatitis C (HCV) or syphilis;

          2. History of immunodeficiency;

          3. Other active infections of clinical significance, based on investigator's judgment;

          4. other concurrent, severe, or uncontrollable systemic diseases ;

          5. History of moderate or severe dyspnea due to advanced malignancy or its complications
             or severe pulmonary primary disease, or the need for continuous oxygen therapy, or
             current interstitial lung disease (ILD) Or pneumonia;

          6. clinically significant Cardiovascular abnormalities according to any of the following
             definitions within 6 months prior to enrollment;

          7. The brain or other central nervous system metastasis symptom;;

          8. There are ≥ 2 grade peripheral neuropathy according to CTCAE5.0（Common Terminology
             Criteria for Adverse Events 5.0）;

          9. Participated in and received other clinical trials within 4 weeks prior to enrollment;

         10. Major surgical treatment within 4 weeks;

         11. Used of strong CYP3A4 inhibitors and have not undergone circulatory clearance (less
             than 3 elimination half-lives) prior to administration of the first clinical study
             drug;

         12. Known allergy to the test drug component, or it is suspected that it may be allergic;

         13. Pregnant or lactating women;

         14. Alcohol abuse, drug abuse or history of drug abuse in the past 6 months;

         15. The investigator believes the patient is not suitable for this trail because of other
             reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jian huang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>qiang wei</last_name>
    <phone>86-20-32203220</phone>
    <email>qwei@bio-thera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jian huang</last_name>
      <email>hjys@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

